These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16259488)

  • 1. Discrepancies in the regulation of plasma adiponectin and TNF-alpha levels and adipose tissue gene expression in obese African Americans with glucose intolerance: a pilot study using rosiglitazone.
    Osei K; Gaillard T; Cook C; Kaplow J; Bullock M; Schuster D
    Ethn Dis; 2005; 15(4):641-8. PubMed ID: 16259488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.
    Osei K; Gaillard T; Schuster D
    Metabolism; 2007 Jan; 56(1):24-9. PubMed ID: 17161222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes.
    Osei K; Gaillard T; Kaplow J; Bullock M; Schuster D
    Metabolism; 2004 Dec; 53(12):1552-7. PubMed ID: 15562399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
    Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes.
    Osei K; Gaillard T; Schuster D
    Obes Res; 2005 Jan; 13(1):179-85. PubMed ID: 15761178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans.
    Chavez AO; Coletta DK; Kamath S; Cromack DT; Monroy A; Folli F; DeFronzo RA; Tripathy D
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E758-64. PubMed ID: 19190263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
    Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
    J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2003 May; 52(5):565-72. PubMed ID: 12759885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
    Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
    Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2004 Apr; 53(4):414-22. PubMed ID: 15045685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
    Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
    Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes.
    Liu HL; Lin YG; Wu J; Sun H; Gong ZC; Hu PC; Yin JY; Zhang W; Wang D; Zhou HH; Liu ZQ
    Eur J Clin Pharmacol; 2008 Jul; 64(7):663-71. PubMed ID: 18438653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
    Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
    Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome in nondiabetic, obese, first-degree relatives of African American patients with type 2 diabetes: African American triglycerides-HDL-C and insulin resistance paradox.
    Meis SB; Schuster D; Gaillard T; Osei K
    Ethn Dis; 2006; 16(4):830-6. PubMed ID: 17061734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.